Passkey Therapeutics utilizes its Locksmith® platform, which employs AI-enhanced computational genetics, to identify synergistic pairs of biological pathways for therapeutic intervention. This technology enables the development of novel drug combinations and multifunctional drugs targeting complex diseases. The company focuses on creating a new class of synergistic therapies by moving beyond the single-target drug development paradigm.
Funding
$22M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
BVFounders
Product
Problem
Conventional drug development typically focuses on single-protein targets, but the biology underlying many diseases is often more complex. This approach may not fully address the intricate mechanisms of diseases like cancer and metabolic disorders. Current treatments may also have undesirable side effects due to their limited scope.
Solution
Passkey Therapeutics is developing Synergistic Multifunctional Therapeutics (SMThs) that target rare protein combinations, known as Multilogs, to address complex diseases. The company's integrated computational and experimental platform, Locksmith, identifies these Multilogs to create new treatment options. By modulating Multilogs instead of individual proteins, Passkey aims to leverage biological complexity for more effective treatments. This approach seeks to create a new generation of medicines for patients with complex diseases.
Target Audience
The primary audience includes patients with complex diseases, as well as pharmaceutical companies seeking novel drug targets and therapeutic approaches.
Features
- Locksmith platform identifies Multilogs, rare combinations of proteins that work together.
- SMThs modulate Multilogs to better treat complex diseases.
- Targets diseases such as cancer, autoimmune and neurodegenerative disorders, and metabolic diseases.